Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS

Biomedical Chromatography

Volumn 26, Issue 9, 2012, Pages 1125-1132

  Fisher, Danielle S ^a   Handley, Simon A ^a   Taylor, David ^b   Flanagan, Robert J ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Concentrations in patient samples; LC MS MS assay; N desalkylquetiapine; Quetiapine; Quetiapine sulfoxide

Indexed keywords

PLASMA (HUMAN); POSITIVE IONS;

ANALYTES; CONCENTRATION IN PATIENT SAMPLE; HUMAN PLASMAS; LC-MS-MS; LC-MS/MS ASSAY; MEASUREMENTS OF; N-DESALKYLQUETIAPINE; PLASMA CONCENTRATION; QUETIAPINE; QUETIAPINE SULPHOXIDE;

METABOLITES;

7 HYDROXYQUETIAPINE 3; AMMONIUM ACETATE; BUTANOL; DRUG METABOLITE; N DESALKYLQUETIAPINE; O DESALKYLQUETIAPINE; QUETIAPINE; QUETIAPINE D8; QUETIAPINE SULFONE; QUETIAPINE SULFOXIDE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FLOW RATE; FOOD AND DRUG ADMINISTRATION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PH; PRACTICE GUIDELINE;

EID: 84864812335     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2672     Document Type: Article

References (17)

1. Atanasov VN, Kanev KP and Mitewa MI. Detection and identification of atypical quetiapine metabolite in urine. Central European Journal of Medicine 2008; 3: 327-331.
2. Bakken GV, Rudberg I, Molden E, Refsum H and Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Therapeutic Drug Monitoring 2011; 33: 222-226.
3. Bellomarino SA, Brown AJ, Conlan XA and Barnett NW. Preliminary evaluation of monolithic column high-performance liquid chromatography with tris(2, 2′-bipyridyl)ruthenium(II) chemiluminescence detection for the determination of quetiapine in human body fluids. Talanta 2008; 77: 1873-1876.
4. Bonfiglio R, King RC, Olah TV and Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Communications in Mass Spectrometry 1999; 13: 1175-1185.
5. Chen J, Gao K and Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Current Opinion in Psychiatry 2011; 24: 10-17.
6. Davis PC, Wong J and Gefvert O. Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. Journal of Pharmaceutical and Biomedical Analysis 1999; 20: 271-282.
7. Davis PC, Bravo O, Gehrke M and Azumaya CT. Development and validation of an LC-MS/MS method for the determination of quetiapine and four related metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2010; 51: 1113-1119.
8. DeVane CL and Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clinical Pharmacokinetics 2001; 40: 509-522.
9. FDA/CDER. Guidance for Industry. Bioanalytical Method Validation, 2001. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed 18 July 2011).
10. Hasselstrom J and Linnet K. Quetiapine serum concentrations in psychiatric patients - the influence of comedication. Therapeutic Drug Monitoring 2004; 26: 486-491.
11. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB and Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1a agonist, as a putative mediator of quetiapine's antidepressant acitivty. Neuropsychopharmacology 2008; 33: 2303-2312.
12. Li K, Cheng Z, Li X, Bai X, Zhang B, Wang F and Li H. Simultaneous determination of quetiapine and three metabolites in human plasma by high-performance liquid chromatography-electrospray ionisation mass spectrometry. Acta Pharmacologica Sinica 2004; 25: 110-114.
13. Morgan PE, Fisher DS and Flanagan RJ. LC-MS/MS of quetiapine: elimination of metabolite interferences. Therapeutic Drug Monitoring 2009; 5: 643.
14. Nikisch G, Baumann P, Kießling B, Reinert M, Wiedemann G, Kehr J, Mathé AA, Piel M, Roesch F, Weisser H, Schneider P and Hertel A. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine. Journal of Psychiatric Research 2010; 44: 759-759.
15. Spina E and de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic and Clinical Pharmacology and Toxicology 2007; 100: 4-22.
16. Tu J-Y, Xu P, Xu D-H and Li H-D. UPLC-MS-MS analysis of quetiapine and its two active metabolites, 7-hydroxyquetiapine and 7-hydroxy-n-dealkylquetiapine, in rat plasma and cerebrospinal fluid. Chromatographia 2008; 6: 525-532.
17. Winter HR, Earley WR, Hamer-Maansson JE, Davis PC and Smith MA. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Journal of Child and Adolescent Psychopharmacology 2008; 18: 81-98.